Share on StockTwits

Auxilium Pharmaceuticals (NASDAQ: AUXL) received a number of price target changes and ratings updates during the last week:

  • Auxilium Pharmaceuticals had its “buy” rating reaffirmed by analysts at UBS AG. They now have a $31.00 price target on the stock.
  • Auxilium Pharmaceuticals had its price target lowered by analysts at RBC Capital from $36.00 to $32.00. They now have an “outperform” rating on the stock.
  • Auxilium Pharmaceuticals had its price target lowered by analysts at Jefferies Group from $39.00 to $34.00. They now have a “buy” rating on the stock.
  • Auxilium Pharmaceuticals had its price target lowered by analysts at Mizuho from $38.00 to $33.00. They now have a “buy” rating on the stock.
  • Auxilium Pharmaceuticals had its price target lowered by analysts at MKM Partners from $29.00 to $26.00. They now have a “neutral” rating on the stock.
  • Auxilium Pharmaceuticals had its price target lowered by analysts at Brean Capital from $17.00 to $14.00. They now have a “sell” rating on the stock.
  • Auxilium Pharmaceuticals was downgraded by analysts at R. F. Lafferty from a “buy” rating to a “neutral” rating. They now have a $19.00 price target on the stock.
  • Auxilium Pharmaceuticals was downgraded by analysts at Cowen and Company from an “outperform” rating to a “market perform” rating. They now have a $21.00 price target on the stock, down previously from $37.00.
  • Auxilium Pharmaceuticals was downgraded by analysts at RF Lafferty & Co. from a “buy” rating to a “hold” rating. They now have a $19.00 price target on the stock.

Auxilium Pharmaceuticals, Inc. (NASDAQ:AUXL) opened at 22.07 on Friday. Auxilium Pharmaceuticals, Inc. has a 52-week low of $14.37 and a 52-week high of $32.89. The stock’s 50-day moving average is $27.33 and its 200-day moving average is $23.52. The company’s market cap is $1.094 billion.

Auxilium Pharmaceuticals, Inc is a specialty biopharmaceutical company focuses on developing and marketing products to predominantly specialist audiences.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.